Skip to content

Lumateperone

SGA • Last reviewed 2025-09-23

Brands: Caplyta

Sources updated 2025 • 1 references

Summary

General Information

Indicated for: Schizophrenia; depressive episodes associated with bipolar I or II (monotherapy or adjunct). Second‑generation antipsychotic (SGA)

Dosage & Administration

Typical dose range: 42 mg/day

Indications (label)

Schizophrenia; depressive episodes associated with bipolar I or II (monotherapy or adjunct).

View labelExact

Mechanism (brief)

5‑HT2A antagonism; D2 presynaptic partial agonist and postsynaptic antagonist; SERT inhibition.

Metabolism & Half‑life

  • Metabolism: Multiple CYP pathways; avoid strong inhibitors/inducers per label.
  • Half‑life: ~18 h.

Therapeutic Drug Monitoring (TDM)

Recommended: No

References